Single high-dose steroid treatment in episodic cluster headache

F. Antonaci, A. Costa, E. Candeloro, O. Sjaastad, G. Nappi

Research output: Contribution to journalArticle

Abstract

Corticosteroids appear to be the most rapid-acting of the prophylactic drugs used in the treatment of cluster headache (CH). These agents are frequently employed as a short-term regimen to induce clinical remission. In this study, we assessed in an open fashion the effect of high dose methylprednisolone (MPD) in a group of 13 patients with episodic CH (3 females and 10 males). On the 8th day of the active period, MPD was administered intravenously at the dose of 30 mg/kg body weight, as a 3-h infusion in saline. The attack frequency was followed for 7 days. The mean daily attack frequency before MPD administration was statistically different from that reported after treatment (respectively: 1.38 ± 0.42 and 0.83 ± 0.78; P = 0.05 Student's t-test). The mean interval between MPD administration and the occurrence of the first subsequent attack was 3.8 ± 2.2 days (range: 2-7 days). Only 3 (23%) of 13 patients experienced a complete headache remission. No significant side-effects were noted after MPD administration. These data further demonstrate that in most patients with episodic CH, high-dose systemic steroid administration may invariably interrupt attack recurrence for a few days, but is ineffective in maintaining complete clinical remission. This study also sugests that MPD administered as a solitary dose does not provide any advantage above prednisone in CH treatment.

Original languageEnglish
Pages (from-to)290-295
Number of pages6
JournalCephalalgia
Volume25
Issue number4
DOIs
Publication statusPublished - Apr 2005

Fingerprint

Cluster Headache
Methylprednisolone
Steroids
Therapeutics
Prednisone
Headache
Adrenal Cortex Hormones
Body Weight
Students
Recurrence
Pharmaceutical Preparations

Keywords

  • Cluster headache
  • Steroid therapy
  • Symptomatic treatment
  • Transitional prophylaxis

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Single high-dose steroid treatment in episodic cluster headache. / Antonaci, F.; Costa, A.; Candeloro, E.; Sjaastad, O.; Nappi, G.

In: Cephalalgia, Vol. 25, No. 4, 04.2005, p. 290-295.

Research output: Contribution to journalArticle

@article{9190f826f2bf41eda013b767280a9ed2,
title = "Single high-dose steroid treatment in episodic cluster headache",
abstract = "Corticosteroids appear to be the most rapid-acting of the prophylactic drugs used in the treatment of cluster headache (CH). These agents are frequently employed as a short-term regimen to induce clinical remission. In this study, we assessed in an open fashion the effect of high dose methylprednisolone (MPD) in a group of 13 patients with episodic CH (3 females and 10 males). On the 8th day of the active period, MPD was administered intravenously at the dose of 30 mg/kg body weight, as a 3-h infusion in saline. The attack frequency was followed for 7 days. The mean daily attack frequency before MPD administration was statistically different from that reported after treatment (respectively: 1.38 ± 0.42 and 0.83 ± 0.78; P = 0.05 Student's t-test). The mean interval between MPD administration and the occurrence of the first subsequent attack was 3.8 ± 2.2 days (range: 2-7 days). Only 3 (23{\%}) of 13 patients experienced a complete headache remission. No significant side-effects were noted after MPD administration. These data further demonstrate that in most patients with episodic CH, high-dose systemic steroid administration may invariably interrupt attack recurrence for a few days, but is ineffective in maintaining complete clinical remission. This study also sugests that MPD administered as a solitary dose does not provide any advantage above prednisone in CH treatment.",
keywords = "Cluster headache, Steroid therapy, Symptomatic treatment, Transitional prophylaxis",
author = "F. Antonaci and A. Costa and E. Candeloro and O. Sjaastad and G. Nappi",
year = "2005",
month = "4",
doi = "10.1111/j.1468-2982.2004.00855.x",
language = "English",
volume = "25",
pages = "290--295",
journal = "Cephalalgia",
issn = "0333-1024",
publisher = "SAGE Publications Ltd",
number = "4",

}

TY - JOUR

T1 - Single high-dose steroid treatment in episodic cluster headache

AU - Antonaci, F.

AU - Costa, A.

AU - Candeloro, E.

AU - Sjaastad, O.

AU - Nappi, G.

PY - 2005/4

Y1 - 2005/4

N2 - Corticosteroids appear to be the most rapid-acting of the prophylactic drugs used in the treatment of cluster headache (CH). These agents are frequently employed as a short-term regimen to induce clinical remission. In this study, we assessed in an open fashion the effect of high dose methylprednisolone (MPD) in a group of 13 patients with episodic CH (3 females and 10 males). On the 8th day of the active period, MPD was administered intravenously at the dose of 30 mg/kg body weight, as a 3-h infusion in saline. The attack frequency was followed for 7 days. The mean daily attack frequency before MPD administration was statistically different from that reported after treatment (respectively: 1.38 ± 0.42 and 0.83 ± 0.78; P = 0.05 Student's t-test). The mean interval between MPD administration and the occurrence of the first subsequent attack was 3.8 ± 2.2 days (range: 2-7 days). Only 3 (23%) of 13 patients experienced a complete headache remission. No significant side-effects were noted after MPD administration. These data further demonstrate that in most patients with episodic CH, high-dose systemic steroid administration may invariably interrupt attack recurrence for a few days, but is ineffective in maintaining complete clinical remission. This study also sugests that MPD administered as a solitary dose does not provide any advantage above prednisone in CH treatment.

AB - Corticosteroids appear to be the most rapid-acting of the prophylactic drugs used in the treatment of cluster headache (CH). These agents are frequently employed as a short-term regimen to induce clinical remission. In this study, we assessed in an open fashion the effect of high dose methylprednisolone (MPD) in a group of 13 patients with episodic CH (3 females and 10 males). On the 8th day of the active period, MPD was administered intravenously at the dose of 30 mg/kg body weight, as a 3-h infusion in saline. The attack frequency was followed for 7 days. The mean daily attack frequency before MPD administration was statistically different from that reported after treatment (respectively: 1.38 ± 0.42 and 0.83 ± 0.78; P = 0.05 Student's t-test). The mean interval between MPD administration and the occurrence of the first subsequent attack was 3.8 ± 2.2 days (range: 2-7 days). Only 3 (23%) of 13 patients experienced a complete headache remission. No significant side-effects were noted after MPD administration. These data further demonstrate that in most patients with episodic CH, high-dose systemic steroid administration may invariably interrupt attack recurrence for a few days, but is ineffective in maintaining complete clinical remission. This study also sugests that MPD administered as a solitary dose does not provide any advantage above prednisone in CH treatment.

KW - Cluster headache

KW - Steroid therapy

KW - Symptomatic treatment

KW - Transitional prophylaxis

UR - http://www.scopus.com/inward/record.url?scp=15944412869&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=15944412869&partnerID=8YFLogxK

U2 - 10.1111/j.1468-2982.2004.00855.x

DO - 10.1111/j.1468-2982.2004.00855.x

M3 - Article

C2 - 15773826

AN - SCOPUS:15944412869

VL - 25

SP - 290

EP - 295

JO - Cephalalgia

JF - Cephalalgia

SN - 0333-1024

IS - 4

ER -